Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M I Freed

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Clinical Pharmacology and Therapeutics|April 1, 1994
Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairmentS C Boike, M A Pue, M I Freed, et al.
Diabetes, Obesity & Metabolism|December 22, 2005
Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) studyJ Rosenstock, B J Goldstein, A I Vinik, et al.
Kidney International|April 12, 2000
Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonismA Wang, T Holcslaw, T M Bashore, et al.
Pharmaceutical Research|May 1, 1996
Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 107647) in rats, dogs, and oncologic patientsD R Brocks, M I Freed, D E Martin, et al.
Journal of Clinical Pharmacology|November 1, 1994
Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteersM I Freed, P R Audet, N Zariffa, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|November 23, 2006
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and EuropeG Viberti, J Lachin, R Holman, et al.
American Journal of Clinical Oncology|April 16, 1998
SK&F107647: a synthetic hematoregulatory peptide in patients with solid tumor malignancies: a phase I trialJ Nemunaitis, D E Martin, D L Willis, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Clinical Pharmacology and Therapeutics|April 1, 1994
Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairmentS C Boike, M A Pue, M I Freed, et al.
Diabetes, Obesity & Metabolism|December 22, 2005
Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) studyJ Rosenstock, B J Goldstein, A I Vinik, et al.
Kidney International|April 12, 2000
Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonismA Wang, T Holcslaw, T M Bashore, et al.
Pharmaceutical Research|May 1, 1996
Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 107647) in rats, dogs, and oncologic patientsD R Brocks, M I Freed, D E Martin, et al.
Journal of Clinical Pharmacology|November 1, 1994
Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteersM I Freed, P R Audet, N Zariffa, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|November 23, 2006
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and EuropeG Viberti, J Lachin, R Holman, et al.
American Journal of Clinical Oncology|April 16, 1998
SK&F107647: a synthetic hematoregulatory peptide in patients with solid tumor malignancies: a phase I trialJ Nemunaitis, D E Martin, D L Willis, et al.
Pageof 3